Podcast Episodes
Back to Search
Episode 523: ESMO 2026: ctDNA Kinetics from Neoadjuvant EVP in MIBC
Jon Chatzkel joins us after his ESMO 2026 presentation to discuss ctDNA results from the KEYNOTE 905 trial.
17 hours ago
Episode 522: ESMO 2026 - KEYNOTE-905 Analysis of Neoadjuvant EVP or Pembro Monotherapy in Cis-ineligible MIBC
Anders Ullen joins the show after his EMSO 2026 presentation looking at KN-905 for the period in which Cis-ineligible MIBC patients were randomized t…
18 hours ago
Episode 521: ESMO 2026 - Reconciling Discrepant Results of Neoadjuvant Chemotherapy + IO in MIBC
Rob Jones joins the show to discuss two phase 3 trials from ESMO 2026 which did not show benefit from chemotherapy + IO vs chemo in MIBC. We discuss …
19 hours ago
Episode 520: ESMO 2026 Preview
Silke, Brian and Tom preview the major data to be presented at ESMO 2026
1 week, 5 days ago
Episode 519: What is the Appropriate Approach to Adjuvant Therapy for UTUC?
Shilpa Gupta joins us to discuss an X poll revealing equipoise about treatment approaches to resected high-risk upper tract urothelial cancer (UTUC).
2 weeks, 5 days ago
Episode 518: PSMAddition in Clinical Practice
Rob Dreicer joins the show to discuss the FDA approval of Lutetium Lu 177 in the mHSPC space and how to contextualize the benefit/risk
3 weeks, 5 days ago
Episode 517: Casdatifan Clinical Data in RCC and Translational Correlates
Toni Choueiri joins Brian and Tom to discuss a recent Nature paper regarding the novel HIF inhibitor, casdatifan, and biomarkers of response.
1 month, 3 weeks ago
Episode 516: The Influence of Hypoxia on Response and Resistance in RCC
Ari Hakimi and Lyn Voung from MSKCC join Brian and Tom to discuss their recent Cancer Cell paper exploring the mechanistic impact of TKI-induced hypo…
2 months ago
Episode 515: PROTEUS - A Reflection on the Data and Controversies with Neha Vapiwala
Brian and Tom invite Neha Vapiwala, a Radiation Oncologist, to discuss areas of consensus and controversy from the PROTEUS trial of ADT +/- apalutami…
2 months, 3 weeks ago
Episode 514: Artificial Intelligence in Cancer Drug Development
Travis Zack, CMO of Open Evidence, joins Brian and Tom to discuss the emergence of AI across the spectrum on cancer, drug development and application…
3 months ago